...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Will we see 5 point MACE reduction results in BETONMACE

More on the secondary endpoint. Looks to me that 5-point MACE is indeed a secondary endpoint. The EU Clinical Trial Register description is by far the most comprehensive of all the sources listed below. Seems that the generic description "hospitalization for CVD events" includes both hospitalization for unstable angina AND hospitalization for emergency revascularization procedures.

From the EU Clinical Trials Register listing for BETonMACE:

"1. Time from randomization to the first occurrence of adjudication-confirmed MACE broadly defined between treatment groups.

Broadly defined MACE is the occurrence of any of the following events:

- CV death

- Non-fatal MI

- Stroke

- Hospitalization for CVD events which include:

o Unstable angina AND evidence of new or presumed new progressive obstructive coronary disease, OR

o Emergency revascularization procedures at any time and urgent revascularization procedures ≥30 days after the index events prior to randomization

2. Time from randomization to CV Death or Non-fatal MI

3. Time from randomization to Non-fatal MI

4. Time from randomization to CV Death

5. Time from randomization to Stroke

6. All-cause mortality"

From ClinicalTrials.gov: "Broadly defined MACE (major adverse cardiac event) is the occurrence of any of the following: CV death, non-fatal MI, hospitalization for CVD events, or stroke"

From the April 2019 Corporate Update: "Secondary endpoints include: hospitalization for unstable angina, emergency revascularization procedures, and all-cause mortality"

From 2018 AGM: "Secondary endpoint includes: hospitalization for unstable angina, emergency revascularization procedures, and all-cause mortality"

From Dr. Ray's 2018 ESC slides: "Secondary Endpoint - Time from randomization to the first occurrence of adjudication-confirmed MACE including revascularization and UA [unstable angina]"

From Dr. Kalantar-Zadeh's 2018 ERA-ETA slides: "Secondary Endpoint - Time from randomization to the first occurrence of adjudication-confirmed MACE including revascularization and unstable angina"

From 2016 R&D Day: "Secondary Endpoint - Time from randomization to the first occurrence of adjudication-confirmed MACE including revascularization and unstable angina"

Share
New Message
Please login to post a reply